Vigilant Biosciences has renewed its contract with Zer0 to 5ive for public relations and marketing services in 2017 to support its OncAlert Oral Cancer and OncAlert Labs product lines in the U.S. and globally.
Finxact, a visionary provider of core banking software-as-a-service, has chosen Zer0 to 5ive to build its brand through messaging, branding, and website design and development.
Vigilant Biosciences® partnered with Zer0 to 5ive to design and develop a new website dedicated exclusively to the Company’s OncAlert® Oral Cancer product line, which includes the OncAlert Oral Cancer RAPID Test and the OncAlert…
After building an award-winning website together, The National Museum of Bermuda decided to enlist the help of Zer0 to 5ive to conceptualize, design, and launch a new ad campaign. The ads will launch leading up…
Crunchbase has selected Zer0 to 5ive to design its year-end global innovation investment report and corresponding gated landing page. The report featured insights from the Crunchbase dataset with tables and graphs to visualize the data.
NTT DOCOMO USA, Inc. a public company that has the largest market share in Japan for consumer mobile communications services, requested Zer0 to 5ive assist in updating its messaging on both its US services and…
Zer0 to 5ive has been selected to support the North American launch of Ehrhardt + Partner’s LFS warehouse management solution. Zer0 to 5ive will be assisting with its development of North America positioning and message…
We are proud to announce that Zer0 to 5ive has been awarded four silver Davey awards for its work in 2016. The winners include the Crunchbase corporate website, the Cloudmine website, cloumineinc.com, the National Museum…
Zer0 to 5ive was honored with two W3 website awards for The National Museum of Bermuda and Cloudmine website design and development projects. The W3 Awards, which honor outstanding websites, web marketing, web video, mobile…
PhotoSonix Medical has tapped Zer0 to 5ive to perform a research study and develop a go-to-market plan for its investigational device Clens which will potentially be deployed in the acne market.
